Dupilumab: Phase IIa data

A double-blind, U.S. Phase IIa trial in 104 patients with moderate to severe persistent asthma showed that once-weekly subcutaneous 300 mg dupilumab met the primary endpoint of reducing the proportion of patients who experienced an asthma exacerbation through week 12 vs. placebo (5.8% vs. 44.2%, p<0.001).

Read the full 468 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE